Daptomycin - Revision history

Aidan at 01:35, 16 July 2024

2024-07-16T01:35:26Z

← Older revision		Revision as of 01:35, 16 July 2024
Line 43:		Line 43:
	\|8 mg/kg IV q48h		\|8 mg/kg IV q48h
	\|}		\|}

			== Safety ==

			* Consider reducing or holding any statins while on daptomycin
			* Monitor CK
			* Monitor for eosinophilic pneumonitis

	[[Category:Cyclic lipopeptides]]		[[Category:Cyclic lipopeptides]]

Aidan: /* Dosing */

2024-07-16T01:34:17Z

Dosing

← Older revision		Revision as of 01:34, 16 July 2024
Line 23:		Line 23:
	=== Renal Dosing ===		=== Renal Dosing ===
	{\| class="wikitable"		{\| class="wikitable"
	!~~GFR~~ (mL/min)		!CrCl (mL/min)
	!Routine Dose		!Routine Dose
	!High Dose		!High Dose
	\|-		\|-
			\|≥30
⚫	\|>50
	\|6 mg/kg IV q24h		\|6 mg/kg IV q24h
	\|8-10 mg/kg IV q24h		\|8-10 mg/kg IV q24h
	\|-		\|-
		⚫	\|>30
	\|11-50
		⚫	\|6 mg/kg IV q48h
	\|
⚫	\|6-8 mg/kg IV ~~q24h~~
	\|-
	\|≤10
	\|
	\|8 mg/kg IV q48h		\|8 mg/kg IV q48h
	\|-		\|-
	\|HD		\|HD
			\|6 mg/kg IV q48h, dosed after dialysis
	\|
	\|8 mg/kg IV q48h, dosed after dialysis		\|8 mg/kg IV q48h, dosed after dialysis
	\|-		\|-
	\|CRRT		\|CRRT
			\|6 mg/kg IV q48h
	\|
	\|8 mg/kg IV q48h		\|8 mg/kg IV q48h
	\|}		\|}

Aidan: /* Dosing */

2023-07-11T22:14:08Z

Dosing

← Older revision		Revision as of 22:14, 11 July 2023
Line 19:		Line 19:
	* Standard dose: 6 mg/kg IV q24h		* Standard dose: 6 mg/kg IV q24h
	* High dose for severe infections, including [[MRSA bacteremia]]: 8 to 10 mg/kg IV q24h		* High dose for severe infections, including [[MRSA bacteremia]]: 8 to 10 mg/kg IV q24h
			* Consider using [[adjusted body weight]] in obesity

	=== Renal Dosing ===		=== Renal Dosing ===

Aidan at 20:13, 30 August 2022

2022-08-30T20:13:00Z

← Older revision		Revision as of 20:13, 30 August 2022
Line 15:		Line 15:
	*Concentration-dependent, best predicted by AUC<sub>24</sub>:MIC		*Concentration-dependent, best predicted by AUC<sub>24</sub>:MIC

			== Dosing ==

			* Standard dose: 6 mg/kg IV q24h
			* High dose for severe infections, including [[MRSA bacteremia]]: 8 to 10 mg/kg IV q24h

			=== Renal Dosing ===
			{\| class="wikitable"
			!GFR (mL/min)
			!Routine Dose
			!High Dose
			\|-
			\|>50
			\|6 mg/kg IV q24h
			\|8-10 mg/kg IV q24h
			\|-
			\|11-50
			\|
			\|6-8 mg/kg IV q24h
			\|-
			\|≤10
			\|
			\|8 mg/kg IV q48h
			\|-
			\|HD
			\|
			\|8 mg/kg IV q48h, dosed after dialysis
			\|-
			\|CRRT
			\|
			\|8 mg/kg IV q48h
			\|}
	[[Category:Cyclic lipopeptides]]		[[Category:Cyclic lipopeptides]]

Aidan at 10:15, 28 September 2020

2020-09-28T10:15:51Z

← Older revision		Revision as of 10:15, 28 September 2020
Line 9:		Line 9:
	===Pharmacokinetics and Pharmacodynamics===		===Pharmacokinetics and Pharmacodynamics===

⚫	*Bactericidal
	*Distributes well into soft tissues and musculoskeletal system, as well as urine		*Distributes well into soft tissues and musculoskeletal system, as well as urine
	**Poor CNS penetration[[CiteRef::piva2019da]]		**Poor CNS penetration[[CiteRef::piva2019da]]
	**Good lung penetration, but is inactivated by lung surfactant and should not be used to treat pneumonia		**Good lung penetration, but is inactivated by lung surfactant and should not be used to treat pneumonia
		⚫	*Bactericidal
			*Concentration-dependent, best predicted by AUC<sub>24</sub>:MIC

	[[Category:Cyclic lipopeptides]]		[[Category:Cyclic lipopeptides]]

Aidan at 18:01, 21 September 2020

2020-09-21T18:01:07Z

← Older revision		Revision as of 18:01, 21 September 2020
Line 11:		Line 11:
	*Bactericidal		*Bactericidal
	*Distributes well into soft tissues and musculoskeletal system, as well as urine		*Distributes well into soft tissues and musculoskeletal system, as well as urine
	**Poor CNS penetration		**Poor CNS penetration[[CiteRef::piva2019da]]
	**Good lung penetration, but is inactivated by lung surfactant and should not be used to treat pneumonia		**Good lung penetration, but is inactivated by lung surfactant and should not be used to treat pneumonia

Aidan at 18:00, 21 September 2020

2020-09-21T18:00:02Z

← Older revision		Revision as of 18:00, 21 September 2020
Line 1:		Line 1:
	== Background ==		==Background==

	*Cyclic lipopeptide antibiotic that is active against Gram-positive bacteria		*Cyclic lipopeptide antibiotic that is active against Gram-positive bacteria

	=== Mechanism of Action ===		===Mechanism of Action===

	*Mechanism of action is to depolarize the cell membrane		*Mechanism of action is to depolarize the cell membrane

	== Pharmacokinetics and Pharmacodynamics ==		===Pharmacokinetics and Pharmacodynamics===

	*Bactericidal		*Bactericidal

Aidan at 17:59, 21 September 2020

2020-09-21T17:59:11Z

← Older revision		Revision as of 17:59, 21 September 2020
Line 1:		Line 1:
			== Background ==
⚫	* Cyclic lipopeptide antibiotic that is active against Gram-positive bacteria

⚫	* Mechanism of action is to depolarize the cell membrane
		⚫	*Cyclic lipopeptide antibiotic that is active against Gram-positive bacteria
⚫	* Bactericidal

			=== Mechanism of Action ===

		⚫	*Mechanism of action is to depolarize the cell membrane

			== Pharmacokinetics and Pharmacodynamics ==

		⚫	*Bactericidal
			*Distributes well into soft tissues and musculoskeletal system, as well as urine
			**Poor CNS penetration
			**Good lung penetration, but is inactivated by lung surfactant and should not be used to treat pneumonia

	[[Category:Cyclic lipopeptides]]		[[Category:Cyclic lipopeptides]]

Aidan: Created page with "* Cyclic lipopeptide antibiotic that is active against Gram-positive bacteria * Mechanism of action is to depolarize the cell membrane * Bactericidal Category:Cyclic lipope..."

2020-01-31T20:08:42Z

Created page with "* Cyclic lipopeptide antibiotic that is active against Gram-positive bacteria * Mechanism of action is to depolarize the cell membrane * Bactericidal Category:Cyclic lipope..."

New page

* Cyclic lipopeptide antibiotic that is active against Gram-positive bacteria
* Mechanism of action is to depolarize the cell membrane
* Bactericidal

[[Category:Cyclic lipopeptides]]